Neurocrine Biosciences (NBIX) Return on Sales (2016 - 2021)
Historic Return on Sales for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to 0.12%.
- Neurocrine Biosciences' Return on Sales rose 600.0% to 0.12% in Q4 2021 from the same period last year, while for Dec 2021 it was 0.12%, marking a year-over-year increase of 600.0%. This contributed to the annual value of 0.05% for FY2019, which is 0.0% changed from last year.
- Latest data reveals that Neurocrine Biosciences reported Return on Sales of 0.12% as of Q4 2021, which was up 600.0% from 0.08% recorded in Q3 2021.
- Neurocrine Biosciences' 5-year Return on Sales high stood at 0.33% for Q3 2018, and its period low was 9.61% during Q2 2017.
- For the 5-year period, Neurocrine Biosciences' Return on Sales averaged around 0.49%, with its median value being 0.12% (2021).
- As far as peak fluctuations go, Neurocrine Biosciences' Return on Sales tumbled by -11600bps in 2017, and later skyrocketed by 95500bps in 2018.
- Neurocrine Biosciences' Return on Sales (Quarter) stood at 0.07% in 2017, then skyrocketed by 96bps to 0.14% in 2018, then fell by -3bps to 0.14% in 2019, then tumbled by -59bps to 0.06% in 2020, then soared by 108bps to 0.12% in 2021.
- Its Return on Sales stands at 0.12% for Q4 2021, versus 0.08% for Q3 2021 and 0.15% for Q2 2021.